Summary of Purpose
The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).Read More →
The following dates are available for this trial. Trial information last updated on 3 August 2017.
|12 Feb 2016||26 Jul 2017||1 Mar 2016||1 Mar 2016||1 Aug 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|